#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Protein and Peptide Nanobiosensors for the Early Diagnosis of Diseases
1-1	0-2	3.	_	_	_	_
1-2	3-10	Protein	substance	new	coref	6-5
1-3	11-14	and	_	_	_	_
1-4	15-22	Peptide	place|object[3]	new|new[3]	coref|coref	5-16[0_3]|14-26
1-5	23-37	Nanobiosensors	object[3]	new[3]	_	_
1-6	38-41	for	object[3]	new[3]	_	_
1-7	42-45	the	object[3]|abstract[4]	new[3]|new[4]	coref	4-12[27_4]
1-8	46-51	Early	object[3]|abstract[4]	new[3]|new[4]	_	_
1-9	52-61	Diagnosis	object[3]|abstract[4]	new[3]|new[4]	_	_
1-10	62-64	of	object[3]|abstract[4]	new[3]|new[4]	_	_
1-11	65-73	Diseases	object[3]|abstract[4]|abstract	new[3]|new[4]|new	coref	4-16

#Text=A pathological process at an early stage is characterized by the appearance of marker proteins at very low ( 10−15 M and lower ) concentrations in blood , and highly-sensitive nanobiosensor systems are required to detect proteins at such low concentrations .
2-1	74-75	A	abstract[6]	new[6]	_	_
2-2	76-88	pathological	abstract[6]	new[6]	_	_
2-3	89-96	process	abstract[6]	new[6]	_	_
2-4	97-99	at	abstract[6]	new[6]	_	_
2-5	100-102	an	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-6	103-108	early	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-7	109-114	stage	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-8	115-117	is	_	_	_	_
2-9	118-131	characterized	_	_	_	_
2-10	132-134	by	_	_	_	_
2-11	135-138	the	abstract[8]	new[8]	_	_
2-12	139-149	appearance	abstract[8]	new[8]	_	_
2-13	150-152	of	abstract[8]	new[8]	_	_
2-14	153-159	marker	abstract[8]|substance[9]	new[8]|new[9]	coref	2-37[0_9]
2-15	160-168	proteins	abstract[8]|substance[9]	new[8]|new[9]	_	_
2-16	169-171	at	abstract[8]	new[8]	_	_
2-17	172-176	very	abstract[8]	new[8]	_	_
2-18	177-180	low	abstract[8]	new[8]	_	_
2-19	181-182	(	abstract[8]	new[8]	_	_
2-20	183-188	10−15	abstract[8]|quantity[10]	new[8]|new[10]	_	_
2-21	189-190	M	abstract[8]|quantity[10]	new[8]|new[10]	_	_
2-22	191-194	and	abstract[8]	new[8]	_	_
2-23	195-200	lower	abstract[8]	new[8]	_	_
2-24	201-202	)	abstract[8]	new[8]	_	_
2-25	203-217	concentrations	abstract[8]|animal[11]	new[8]|new[11]	coref	2-39[16_11]
2-26	218-220	in	abstract[8]|animal[11]	new[8]|new[11]	_	_
2-27	221-226	blood	abstract[8]|animal[11]|substance	new[8]|new[11]|new	_	_
2-28	227-228	,	_	_	_	_
2-29	229-232	and	_	_	_	_
2-30	233-249	highly-sensitive	object[14]	new[14]	coref	16-7[226_14]
2-31	250-263	nanobiosensor	person|object[14]	new|new[14]	_	_
2-32	264-271	systems	object[14]	new[14]	_	_
2-33	272-275	are	_	_	_	_
2-34	276-284	required	_	_	_	_
2-35	285-287	to	_	_	_	_
2-36	288-294	detect	_	_	_	_
2-37	295-303	proteins	substance	giv	coref	5-62[50_0]
2-38	304-306	at	_	_	_	_
2-39	307-311	such	animal[16]	giv[16]	coref	6-7[61_16]
2-40	312-315	low	animal[16]	giv[16]	_	_
2-41	316-330	concentrations	animal[16]	giv[16]	_	_
2-42	331-332	.	_	_	_	_

#Text=Additionally , the composition of biomolecules gathering at a surface is another relevant issue , given the dynamic nature of disease progression .
3-1	333-345	Additionally	_	_	_	_
3-2	346-347	,	_	_	_	_
3-3	348-351	the	abstract[17]	new[17]	coref	3-12[20_17]
3-4	352-363	composition	abstract[17]	new[17]	_	_
3-5	364-366	of	abstract[17]	new[17]	_	_
3-6	367-379	biomolecules	abstract[17]|substance	new[17]|new	_	_
3-7	380-389	gathering	_	_	_	_
3-8	390-392	at	_	_	_	_
3-9	393-394	a	place[19]	new[19]	coref	11-27[0_19]
3-10	395-402	surface	place[19]	new[19]	_	_
3-11	403-405	is	_	_	_	_
3-12	406-413	another	abstract[20]	giv[20]	coref	12-24[167_20]
3-13	414-422	relevant	abstract[20]	giv[20]	_	_
3-14	423-428	issue	abstract[20]	giv[20]	_	_
3-15	429-430	,	_	_	_	_
3-16	431-436	given	_	_	_	_
3-17	437-440	the	abstract[21]	new[21]	_	_
3-18	441-448	dynamic	abstract[21]	new[21]	_	_
3-19	449-455	nature	abstract[21]	new[21]	_	_
3-20	456-458	of	abstract[21]	new[21]	_	_
3-21	459-466	disease	abstract[21]|abstract|abstract[23]	new[21]|new|new[23]	_	_
3-22	467-478	progression	abstract[21]|abstract[23]	new[21]|new[23]	_	_
3-23	479-480	.	_	_	_	_

#Text=With respect to that , nano-biosensors may offer increased possibilities for the early diagnosis of diseases .
4-1	481-485	With	_	_	_	_
4-2	486-493	respect	abstract[24]	new[24]	_	_
4-3	494-496	to	abstract[24]	new[24]	_	_
4-4	497-501	that	abstract[24]	new[24]	_	_
4-5	502-503	,	_	_	_	_
4-6	504-519	nano-biosensors	object	new	_	_
4-7	520-523	may	_	_	_	_
4-8	524-529	offer	_	_	_	_
4-9	530-539	increased	abstract[26]	new[26]	_	_
4-10	540-553	possibilities	abstract[26]	new[26]	_	_
4-11	554-557	for	abstract[26]	new[26]	_	_
4-12	558-561	the	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
4-13	562-567	early	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
4-14	568-577	diagnosis	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
4-15	578-580	of	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
4-16	581-589	diseases	abstract[26]|abstract[27]|abstract	new[26]|giv[27]|giv	_	_
4-17	590-591	.	_	_	_	_

#Text=In the manuscript : Influence of Chip Materials on Charge Generation in Flowing Solution in Nanobiosensors , Y.D. Ivanov and coworkers demonstrate that the presence of an AFM chip ( made of mica and graphite ) near the nozzle of the injector supplying an analyte solution into the measuring cell of an AFM-based fishing system ( used for the registration of low-abundant proteins in the temperature range corresponding to the physiological temperature of 35 °C ) causes an increase in charge generation upon the injection of the solution .
5-1	592-594	In	_	_	_	_
5-2	595-598	the	object[29]	new[29]	_	_
5-3	599-609	manuscript	object[29]	new[29]	_	_
5-4	610-611	:	_	_	_	_
5-5	612-621	Influence	abstract[30]	new[30]	_	_
5-6	622-624	of	abstract[30]	new[30]	_	_
5-7	625-629	Chip	abstract[30]|object|object[32]	new[30]|new|new[32]	_	_
5-8	630-639	Materials	abstract[30]|object[32]	new[30]|new[32]	_	_
5-9	640-642	on	abstract[30]	new[30]	_	_
5-10	643-649	Charge	abstract[30]|person|abstract[34]	new[30]|new|new[34]	coref	5-81[56_34]
5-11	650-660	Generation	abstract[30]|abstract[34]	new[30]|new[34]	_	_
5-12	661-663	in	abstract[30]|abstract[34]	new[30]|new[34]	_	_
5-13	664-671	Flowing	abstract[30]|abstract[34]|substance[35]	new[30]|new[34]|new[35]	coref	5-44[45_35]
5-14	672-680	Solution	abstract[30]|abstract[34]|substance[35]	new[30]|new[34]|new[35]	_	_
5-15	681-683	in	abstract[30]|abstract[34]|substance[35]	new[30]|new[34]|new[35]	_	_
5-16	684-698	Nanobiosensors	abstract[30]|abstract[34]|substance[35]|object	new[30]|new[34]|new[35]|giv	_	_
5-17	699-700	,	abstract[30]|abstract[34]|substance[35]	new[30]|new[34]|new[35]	_	_
5-18	701-705	Y.D.	abstract[30]|abstract[34]|substance[35]|person[37]	new[30]|new[34]|new[35]|new[37]	_	_
5-19	706-712	Ivanov	abstract[30]|abstract[34]|substance[35]|person[37]	new[30]|new[34]|new[35]|new[37]	_	_
5-20	713-716	and	abstract[30]|abstract[34]|substance[35]	new[30]|new[34]|new[35]	_	_
5-21	717-726	coworkers	abstract[30]|abstract[34]|substance[35]|person	new[30]|new[34]|new[35]|new	coref	7-4[68_0]
5-22	727-738	demonstrate	_	_	_	_
5-23	739-743	that	_	_	_	_
5-24	744-747	the	abstract[39]	new[39]	_	_
5-25	748-756	presence	abstract[39]	new[39]	_	_
5-26	757-759	of	abstract[39]	new[39]	_	_
5-27	760-762	an	abstract[39]|object[40]	new[39]|new[40]	_	_
5-28	763-766	AFM	abstract[39]|object[40]	new[39]|new[40]	_	_
5-29	767-771	chip	abstract[39]|object[40]	new[39]|new[40]	_	_
5-30	772-773	(	_	_	_	_
5-31	774-778	made	_	_	_	_
5-32	779-781	of	_	_	_	_
5-33	782-786	mica	substance	new	_	_
5-34	787-790	and	_	_	_	_
5-35	791-799	graphite	abstract	new	_	_
5-36	800-801	)	_	_	_	_
5-37	802-806	near	_	_	_	_
5-38	807-810	the	object[43]	new[43]	_	_
5-39	811-817	nozzle	object[43]	new[43]	_	_
5-40	818-820	of	object[43]	new[43]	_	_
5-41	821-824	the	object[43]|object[44]	new[43]|new[44]	coref	6-19[66_44]
5-42	825-833	injector	object[43]|object[44]	new[43]|new[44]	_	_
5-43	834-843	supplying	_	_	_	_
5-44	844-846	an	substance[45]	giv[45]	coref	5-87[58_45]
5-45	847-854	analyte	substance[45]	giv[45]	_	_
5-46	855-863	solution	substance[45]	giv[45]	_	_
5-47	864-868	into	substance[45]	giv[45]	_	_
5-48	869-872	the	substance[45]|object[46]	giv[45]|new[46]	_	_
5-49	873-882	measuring	substance[45]|object[46]	giv[45]|new[46]	_	_
5-50	883-887	cell	substance[45]|object[46]	giv[45]|new[46]	_	_
5-51	888-890	of	substance[45]|object[46]	giv[45]|new[46]	_	_
5-52	891-893	an	substance[45]|object[46]|abstract[48]	giv[45]|new[46]|new[48]	_	_
5-53	894-903	AFM-based	substance[45]|object[46]|abstract[48]	giv[45]|new[46]|new[48]	_	_
5-54	904-911	fishing	substance[45]|object[46]|object|abstract[48]	giv[45]|new[46]|new|new[48]	_	_
5-55	912-918	system	substance[45]|object[46]|abstract[48]	giv[45]|new[46]|new[48]	_	_
5-56	919-920	(	_	_	_	_
5-57	921-925	used	_	_	_	_
5-58	926-929	for	_	_	_	_
5-59	930-933	the	abstract[49]	new[49]	_	_
5-60	934-946	registration	abstract[49]	new[49]	_	_
5-61	947-949	of	abstract[49]	new[49]	_	_
5-62	950-962	low-abundant	abstract[49]|substance[50]	new[49]|giv[50]	_	_
5-63	963-971	proteins	abstract[49]|substance[50]	new[49]|giv[50]	_	_
5-64	972-974	in	abstract[49]	new[49]	_	_
5-65	975-978	the	abstract[49]|abstract[52]	new[49]|new[52]	coref	11-45[153_52]
5-66	979-990	temperature	abstract[49]|abstract|abstract[52]	new[49]|new|new[52]	coref	5-70[53_0]
5-67	991-996	range	abstract[49]|abstract[52]	new[49]|new[52]	_	_
5-68	997-1010	corresponding	_	_	_	_
5-69	1011-1013	to	_	_	_	_
5-70	1014-1017	the	abstract[53]	giv[53]	_	_
5-71	1018-1031	physiological	abstract[53]	giv[53]	_	_
5-72	1032-1043	temperature	abstract[53]	giv[53]	_	_
5-73	1044-1046	of	abstract[53]	giv[53]	_	_
5-74	1047-1049	35	abstract[53]|quantity[54]	giv[53]|new[54]	_	_
5-75	1050-1052	°C	abstract[53]|quantity[54]	giv[53]|new[54]	_	_
5-76	1053-1054	)	_	_	_	_
5-77	1055-1061	causes	_	_	_	_
5-78	1062-1064	an	abstract[55]	new[55]	coref	6-10[62_55]
5-79	1065-1073	increase	abstract[55]	new[55]	_	_
5-80	1074-1076	in	abstract[55]	new[55]	_	_
5-81	1077-1083	charge	abstract[55]|abstract[56]	new[55]|giv[56]	coref	6-16[65_56]
5-82	1084-1094	generation	abstract[55]|abstract[56]	new[55]|giv[56]	_	_
5-83	1095-1099	upon	abstract[55]|abstract[56]	new[55]|giv[56]	_	_
5-84	1100-1103	the	abstract[55]|abstract[56]|event[57]	new[55]|giv[56]|new[57]	_	_
5-85	1104-1113	injection	abstract[55]|abstract[56]|event[57]	new[55]|giv[56]|new[57]	_	_
5-86	1114-1116	of	abstract[55]|abstract[56]|event[57]	new[55]|giv[56]|new[57]	_	_
5-87	1117-1120	the	abstract[55]|abstract[56]|event[57]|substance[58]	new[55]|giv[56]|new[57]|giv[58]	_	_
5-88	1121-1129	solution	abstract[55]|abstract[56]|event[57]|substance[58]	new[55]|giv[56]|new[57]|giv[58]	_	_
5-89	1130-1131	.	_	_	_	_

#Text=In the presence of protein at femtomolar concentrations , an increase in the efficiency of charge generation in the injector was demonstrated .
6-1	1132-1134	In	_	_	_	_
6-2	1135-1138	the	abstract[59]	new[59]	_	_
6-3	1139-1147	presence	abstract[59]	new[59]	_	_
6-4	1148-1150	of	abstract[59]	new[59]	_	_
6-5	1151-1158	protein	abstract[59]|substance	new[59]|giv	coref	18-45
6-6	1159-1161	at	abstract[59]	new[59]	_	_
6-7	1162-1172	femtomolar	abstract[59]|animal[61]	new[59]|giv[61]	_	_
6-8	1173-1187	concentrations	abstract[59]|animal[61]	new[59]|giv[61]	_	_
6-9	1188-1189	,	_	_	_	_
6-10	1190-1192	an	abstract[62]	giv[62]	_	_
6-11	1193-1201	increase	abstract[62]	giv[62]	_	_
6-12	1202-1204	in	abstract[62]	giv[62]	_	_
6-13	1205-1208	the	abstract[62]|abstract[63]	giv[62]|new[63]	_	_
6-14	1209-1219	efficiency	abstract[62]|abstract[63]	giv[62]|new[63]	_	_
6-15	1220-1222	of	abstract[62]|abstract[63]	giv[62]|new[63]	_	_
6-16	1223-1229	charge	abstract[62]|abstract[63]|abstract|abstract[65]	giv[62]|new[63]|new|giv[65]	_	_
6-17	1230-1240	generation	abstract[62]|abstract[63]|abstract[65]	giv[62]|new[63]|giv[65]	_	_
6-18	1241-1243	in	abstract[62]|abstract[63]|abstract[65]	giv[62]|new[63]|giv[65]	_	_
6-19	1244-1247	the	abstract[62]|abstract[63]|abstract[65]|object[66]	giv[62]|new[63]|giv[65]|giv[66]	_	_
6-20	1248-1256	injector	abstract[62]|abstract[63]|abstract[65]|object[66]	giv[62]|new[63]|giv[65]|giv[66]	_	_
6-21	1257-1260	was	_	_	_	_
6-22	1261-1273	demonstrated	_	_	_	_
6-23	1274-1275	.	_	_	_	_

#Text=G.Z. Gayda and coworkers in their paper on Metallic Nanoparticles Obtained via “ Green ” Synthesis as a Platform for Biosensor Construction demonstrate the possibility of developing reagent-less , enzyme-based amperometric biosensors using metallic nanoparticles obtained via green synthesis ( gNPs ) , which have great potential for applications in biotechnology , industry , and medicine as antibacterial agents , fluorescent markers , and carriers for drug delivery , respectively .
7-1	1276-1280	G.Z.	person[67]	new[67]	_	_
7-2	1281-1286	Gayda	person[67]	new[67]	_	_
7-3	1287-1290	and	_	_	_	_
7-4	1291-1300	coworkers	person[68]	giv[68]	coref	10-33[0_68]
7-5	1301-1303	in	person[68]	giv[68]	_	_
7-6	1304-1309	their	person[68]|abstract[69]	giv[68]|new[69]	coref	13-6[175_69]
7-7	1310-1315	paper	person[68]|abstract[69]	giv[68]|new[69]	_	_
7-8	1316-1318	on	person[68]|abstract[69]	giv[68]|new[69]	_	_
7-9	1319-1327	Metallic	person[68]|abstract[69]|object[70]	giv[68]|new[69]|new[70]	coref	7-34[79_70]
7-10	1328-1341	Nanoparticles	person[68]|abstract[69]|object[70]	giv[68]|new[69]|new[70]	_	_
7-11	1342-1350	Obtained	_	_	_	_
7-12	1351-1354	via	_	_	_	_
7-13	1355-1356	“	abstract[72]	new[72]	coref	7-38[80_72]
7-14	1357-1362	Green	person|abstract[72]	new|new[72]	_	_
7-15	1363-1364	”	abstract[72]	new[72]	_	_
7-16	1365-1374	Synthesis	abstract[72]	new[72]	_	_
7-17	1375-1377	as	abstract[72]	new[72]	_	_
7-18	1378-1379	a	abstract[72]	new[72]	_	_
7-19	1380-1388	Platform	abstract[72]	new[72]	_	_
7-20	1389-1392	for	abstract[72]	new[72]	_	_
7-21	1393-1402	Biosensor	abstract[72]|place|place[74]	new[72]|new|new[74]	coref	18-7
7-22	1403-1415	Construction	abstract[72]|place[74]	new[72]|new[74]	_	_
7-23	1416-1427	demonstrate	_	_	_	_
7-24	1428-1431	the	abstract[75]	new[75]	_	_
7-25	1432-1443	possibility	abstract[75]	new[75]	_	_
7-26	1444-1446	of	_	_	_	_
7-27	1447-1457	developing	_	_	_	_
7-28	1458-1470	reagent-less	object	new	_	_
7-29	1471-1472	,	_	_	_	_
7-30	1473-1485	enzyme-based	_	_	_	_
7-31	1486-1498	amperometric	abstract|substance[78]	new|new[78]	coref	9-49[115_78]
7-32	1499-1509	biosensors	substance[78]	new[78]	_	_
7-33	1510-1515	using	_	_	_	_
7-34	1516-1524	metallic	object[79]	giv[79]	coref	13-15[179_79]
7-35	1525-1538	nanoparticles	object[79]	giv[79]	_	_
7-36	1539-1547	obtained	_	_	_	_
7-37	1548-1551	via	_	_	_	_
7-38	1552-1557	green	abstract[80]	giv[80]	appos	7-41[0_80]
7-39	1558-1567	synthesis	abstract[80]	giv[80]	_	_
7-40	1568-1569	(	_	_	_	_
7-41	1570-1574	gNPs	abstract	giv	coref	8-5[92_0]
7-42	1575-1576	)	_	_	_	_
7-43	1577-1578	,	_	_	_	_
7-44	1579-1584	which	_	_	_	_
7-45	1585-1589	have	_	_	_	_
7-46	1590-1595	great	abstract[82]	new[82]	_	_
7-47	1596-1605	potential	abstract[82]	new[82]	_	_
7-48	1606-1609	for	abstract[82]	new[82]	_	_
7-49	1610-1622	applications	abstract[82]|abstract[83]	new[82]|new[83]	coref	13-35[188_83]
7-50	1623-1625	in	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-51	1626-1639	biotechnology	abstract[82]|abstract[83]|abstract	new[82]|new[83]|new	_	_
7-52	1640-1641	,	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-53	1642-1650	industry	abstract[82]|abstract[83]|abstract	new[82]|new[83]|new	_	_
7-54	1651-1652	,	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-55	1653-1656	and	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-56	1657-1665	medicine	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-57	1666-1668	as	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-58	1669-1682	antibacterial	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-59	1683-1689	agents	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-60	1690-1691	,	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-61	1692-1703	fluorescent	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-62	1704-1711	markers	abstract[82]|abstract[83]|abstract[86]	new[82]|new[83]|new[86]	_	_
7-63	1712-1713	,	_	_	_	_
7-64	1714-1717	and	_	_	_	_
7-65	1718-1726	carriers	organization[87]	new[87]	_	_
7-66	1727-1730	for	organization[87]	new[87]	_	_
7-67	1731-1735	drug	organization[87]|substance|abstract[89]	new[87]|new|new[89]	_	_
7-68	1736-1744	delivery	organization[87]|abstract[89]	new[87]|new[89]	_	_
7-69	1745-1746	,	organization[87]	new[87]	_	_
7-70	1747-1759	respectively	organization[87]	new[87]	_	_
7-71	1760-1761	.	_	_	_	_

#Text=The bioelectrodes modified with Pd-based gNPs have lower sensitivities to their substrates , but broader linear ranges of their detection and higher storage stabilities than unmodified control electrodes .
8-1	1762-1765	The	substance[90]	new[90]	_	_
8-2	1766-1779	bioelectrodes	substance[90]	new[90]	_	_
8-3	1780-1788	modified	_	_	_	_
8-4	1789-1793	with	_	_	_	_
8-5	1794-1802	Pd-based	abstract|abstract[92]	new|giv[92]	coref	9-23[109_92]
8-6	1803-1807	gNPs	abstract[92]	giv[92]	_	_
8-7	1808-1812	have	_	_	_	_
8-8	1813-1818	lower	abstract[93]|abstract[94]	new[93]|new[94]	_	_
8-9	1819-1832	sensitivities	abstract[93]|abstract[94]	new[93]|new[94]	_	_
8-10	1833-1835	to	abstract[93]|abstract[94]	new[93]|new[94]	_	_
8-11	1836-1841	their	abstract[93]|abstract[94]|object[95]	new[93]|new[94]|new[95]	_	_
8-12	1842-1852	substrates	abstract[93]|abstract[94]|object[95]	new[93]|new[94]|new[95]	_	_
8-13	1853-1854	,	abstract[94]	new[94]	_	_
8-14	1855-1858	but	abstract[94]	new[94]	_	_
8-15	1859-1866	broader	abstract[94]|abstract[96]	new[94]|new[96]	_	_
8-16	1867-1873	linear	abstract[94]|abstract[96]	new[94]|new[96]	_	_
8-17	1874-1880	ranges	abstract[94]|abstract[96]	new[94]|new[96]	_	_
8-18	1881-1883	of	abstract[94]|abstract[96]	new[94]|new[96]	_	_
8-19	1884-1889	their	abstract[94]|abstract[96]|abstract[97]	new[94]|new[96]|new[97]	coref	13-19[181_97]
8-20	1890-1899	detection	abstract[94]|abstract[96]|abstract[97]	new[94]|new[96]|new[97]	_	_
8-21	1900-1903	and	abstract[94]|abstract[96]	new[94]|new[96]	_	_
8-22	1904-1910	higher	abstract[94]|abstract[96]|abstract[99]	new[94]|new[96]|new[99]	_	_
8-23	1911-1918	storage	abstract[94]|abstract[96]|place|abstract[99]	new[94]|new[96]|new|new[99]	_	_
8-24	1919-1930	stabilities	abstract[94]|abstract[96]|abstract[99]	new[94]|new[96]|new[99]	_	_
8-25	1931-1935	than	abstract[94]|abstract[96]|abstract[99]	new[94]|new[96]|new[99]	_	_
8-26	1936-1946	unmodified	abstract[94]|abstract[96]|abstract[99]|object[101]	new[94]|new[96]|new[99]|new[101]	coref	19-4[261_101]
8-27	1947-1954	control	abstract[94]|abstract[96]|abstract[99]|abstract|object[101]	new[94]|new[96]|new[99]|new|new[101]	_	_
8-28	1955-1965	electrodes	abstract[94]|abstract[96]|abstract[99]|object[101]	new[94]|new[96]|new[99]|new[101]	_	_
8-29	1966-1967	.	_	_	_	_

#Text=Moreover , the advantage of the “ green ” approach is the rapid growth of the yeast cells with a high-yield of pure gNPs surrounded by organic compounds that provides the anti-aggregative effect on metallic gNPs , which can be useful as carriers of enzymes and cells in biosensors and biofuel cells .
9-1	1968-1976	Moreover	_	_	_	_
9-2	1977-1978	,	_	_	_	_
9-3	1979-1982	the	abstract[102]	new[102]	coref	9-12[105_102]
9-4	1983-1992	advantage	abstract[102]	new[102]	_	_
9-5	1993-1995	of	abstract[102]	new[102]	_	_
9-6	1996-1999	the	abstract[102]|abstract[104]	new[102]|new[104]	_	_
9-7	2000-2001	“	abstract[102]|abstract[104]	new[102]|new[104]	_	_
9-8	2002-2007	green	abstract[102]|abstract|abstract[104]	new[102]|new|new[104]	_	_
9-9	2008-2009	”	abstract[102]|abstract[104]	new[102]|new[104]	_	_
9-10	2010-2018	approach	abstract[102]|abstract[104]	new[102]|new[104]	_	_
9-11	2019-2021	is	_	_	_	_
9-12	2022-2025	the	abstract[105]	giv[105]	_	_
9-13	2026-2031	rapid	abstract[105]	giv[105]	_	_
9-14	2032-2038	growth	abstract[105]	giv[105]	_	_
9-15	2039-2041	of	abstract[105]	giv[105]	_	_
9-16	2042-2045	the	abstract[105]|object[107]	giv[105]|new[107]	coref	9-47[114_107]
9-17	2046-2051	yeast	abstract[105]|substance|object[107]	giv[105]|new|new[107]	_	_
9-18	2052-2057	cells	abstract[105]|object[107]	giv[105]|new[107]	_	_
9-19	2058-2062	with	abstract[105]|object[107]	giv[105]|new[107]	_	_
9-20	2063-2064	a	abstract[105]|object[107]|quantity[108]	giv[105]|new[107]|new[108]	_	_
9-21	2065-2075	high-yield	abstract[105]|object[107]|quantity[108]	giv[105]|new[107]|new[108]	_	_
9-22	2076-2078	of	abstract[105]|object[107]|quantity[108]	giv[105]|new[107]|new[108]	_	_
9-23	2079-2083	pure	abstract[105]|object[107]|quantity[108]|abstract[109]	giv[105]|new[107]|new[108]|giv[109]	coref	9-35[112_109]
9-24	2084-2088	gNPs	abstract[105]|object[107]|quantity[108]|abstract[109]	giv[105]|new[107]|new[108]|giv[109]	_	_
9-25	2089-2099	surrounded	_	_	_	_
9-26	2100-2102	by	_	_	_	_
9-27	2103-2110	organic	substance[110]	new[110]	_	_
9-28	2111-2120	compounds	substance[110]	new[110]	_	_
9-29	2121-2125	that	_	_	_	_
9-30	2126-2134	provides	_	_	_	_
9-31	2135-2138	the	abstract[111]	new[111]	_	_
9-32	2139-2155	anti-aggregative	abstract[111]	new[111]	_	_
9-33	2156-2162	effect	abstract[111]	new[111]	_	_
9-34	2163-2165	on	abstract[111]	new[111]	_	_
9-35	2166-2174	metallic	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
9-36	2175-2179	gNPs	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
9-37	2180-2181	,	_	_	_	_
9-38	2182-2187	which	_	_	_	_
9-39	2188-2191	can	_	_	_	_
9-40	2192-2194	be	_	_	_	_
9-41	2195-2201	useful	_	_	_	_
9-42	2202-2204	as	_	_	_	_
9-43	2205-2213	carriers	_	_	_	_
9-44	2214-2216	of	_	_	_	_
9-45	2217-2224	enzymes	substance	new	_	_
9-46	2225-2228	and	_	_	_	_
9-47	2229-2234	cells	object[114]	giv[114]	coref	20-18[272_114]
9-48	2235-2237	in	object[114]	giv[114]	_	_
9-49	2238-2248	biosensors	object[114]|substance[115]	giv[114]|giv[115]	coref	18-25[0_115]
9-50	2249-2252	and	object[114]|substance[115]	giv[114]|giv[115]	_	_
9-51	2253-2260	biofuel	object[114]|substance[115]	giv[114]|giv[115]	_	_
9-52	2261-2266	cells	object[114]|substance[115]	giv[114]|giv[115]	_	_
9-53	2267-2268	.	_	_	_	_

#Text=In the article on The Characterisation and Quantification of Immobilised Concanavalin A on Quartz Surfaces Based on The Competitive Binding to Glucose and Fluorescent Labelled Dextran authored by T. Bich Hoang and coworkers , a simple protocol for the immobilization of Concanavalin A ( Con A ) on a quartz substrate , a common material for gravimetric microsensors , was developed .
10-1	2269-2271	In	_	_	_	_
10-2	2272-2275	the	abstract[116]	new[116]	_	_
10-3	2276-2283	article	abstract[116]	new[116]	_	_
10-4	2284-2286	on	abstract[116]	new[116]	_	_
10-5	2287-2290	The	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-6	2291-2307	Characterisation	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-7	2308-2311	and	abstract[116]	new[116]	_	_
10-8	2312-2326	Quantification	abstract[116]|abstract[118]	new[116]|new[118]	_	_
10-9	2327-2329	of	abstract[116]|abstract[118]	new[116]|new[118]	_	_
10-10	2330-2341	Immobilised	abstract[116]|abstract[118]|abstract|substance[120]	new[116]|new[118]|new|new[120]	coref	10-42[0_120]
10-11	2342-2354	Concanavalin	abstract[116]|abstract[118]|substance[120]	new[116]|new[118]|new[120]	_	_
10-12	2355-2356	A	abstract[116]|abstract[118]|substance[120]|object[122]	new[116]|new[118]|new[120]|new[122]	_	_
10-13	2357-2359	on	abstract[116]|abstract[118]|substance[120]|object[122]	new[116]|new[118]|new[120]|new[122]	_	_
10-14	2360-2366	Quartz	abstract[116]|abstract[118]|substance[120]|abstract|object[122]	new[116]|new[118]|new[120]|new|new[122]	coref	10-50
10-15	2367-2375	Surfaces	abstract[116]|abstract[118]|substance[120]|object[122]	new[116]|new[118]|new[120]|new[122]	_	_
10-16	2376-2381	Based	_	_	_	_
10-17	2382-2384	on	_	_	_	_
10-18	2385-2388	The	abstract[123]	new[123]	_	_
10-19	2389-2400	Competitive	abstract[123]	new[123]	_	_
10-20	2401-2408	Binding	object[124]	new[124]	coref	11-2[0_124]
10-21	2409-2411	to	object[124]	new[124]	_	_
10-22	2412-2419	Glucose	object[124]|substance	new[124]|new	coref	11-46
10-23	2420-2423	and	object[124]	new[124]	_	_
10-24	2424-2435	Fluorescent	object[124]|abstract	new[124]|new	_	_
10-25	2436-2444	Labelled	object[124]|abstract|substance[128]	new[124]|new|new[128]	coref	11-18[0_128]
10-26	2445-2452	Dextran	object[124]|substance[128]	new[124]|new[128]	_	_
10-27	2453-2461	authored	_	_	_	_
10-28	2462-2464	by	_	_	_	_
10-29	2465-2467	T.	person[129]	new[129]	_	_
10-30	2468-2472	Bich	person[129]	new[129]	_	_
10-31	2473-2478	Hoang	person[129]	new[129]	_	_
10-32	2479-2482	and	_	_	_	_
10-33	2483-2492	coworkers	person	giv	coref	13-4[174_0]
10-34	2493-2494	,	_	_	_	_
10-35	2495-2496	a	abstract[131]	new[131]	_	_
10-36	2497-2503	simple	abstract[131]	new[131]	_	_
10-37	2504-2512	protocol	abstract[131]	new[131]	_	_
10-38	2513-2516	for	abstract[131]	new[131]	_	_
10-39	2517-2520	the	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-40	2521-2535	immobilization	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-41	2536-2538	of	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-42	2539-2551	Concanavalin	abstract[131]|abstract[132]|substance	new[131]|new[132]|giv	_	_
10-43	2552-2553	A	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-44	2554-2555	(	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-45	2556-2559	Con	abstract[131]|abstract[132]|person[134]	new[131]|new[132]|new[134]	_	_
10-46	2560-2561	A	abstract[131]|abstract[132]|person[134]	new[131]|new[132]|new[134]	_	_
10-47	2562-2563	)	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-48	2564-2566	on	abstract[131]|abstract[132]	new[131]|new[132]	_	_
10-49	2567-2568	a	abstract[131]|abstract[132]|object[136]	new[131]|new[132]|new[136]	appos	10-53[137_136]
10-50	2569-2575	quartz	abstract[131]|abstract[132]|substance|object[136]	new[131]|new[132]|giv|new[136]	_	_
10-51	2576-2585	substrate	abstract[131]|abstract[132]|object[136]	new[131]|new[132]|new[136]	_	_
10-52	2586-2587	,	_	_	_	_
10-53	2588-2589	a	object[137]	giv[137]	coref	19-4[0_137]
10-54	2590-2596	common	object[137]	giv[137]	_	_
10-55	2597-2605	material	object[137]	giv[137]	_	_
10-56	2606-2609	for	object[137]	giv[137]	_	_
10-57	2610-2621	gravimetric	object[137]|object[138]	giv[137]|new[138]	_	_
10-58	2622-2634	microsensors	object[137]|object[138]	giv[137]|new[138]	_	_
10-59	2635-2636	,	_	_	_	_
10-60	2637-2640	was	_	_	_	_
10-61	2641-2650	developed	_	_	_	_
10-62	2651-2652	.	_	_	_	_

#Text=The binding activity of the immobilized Con A was assessed by measuring the intensity from fluorescent labelled dextran ( FITC and Alexa 488 ; with a surface coverage ranging from 1.8 × 1011 to 2.1 × 1012 immobilized fluorescent molecules per cm2 ) over a glucose concentration range from 0 to 40 mM , whereas any structural changes to the surface topography were investigated using AFM .
11-1	2653-2656	The	abstract[140]	new[140]	coref	15-1[217_140]
11-2	2657-2664	binding	object|abstract[140]	giv|new[140]	_	_
11-3	2665-2673	activity	abstract[140]	new[140]	_	_
11-4	2674-2676	of	abstract[140]	new[140]	_	_
11-5	2677-2680	the	abstract[140]	new[140]	_	_
11-6	2681-2692	immobilized	abstract[140]	new[140]	_	_
11-7	2693-2696	Con	abstract[140]	new[140]	_	_
11-8	2697-2698	A	abstract[140]	new[140]	_	_
11-9	2699-2702	was	_	_	_	_
11-10	2703-2711	assessed	_	_	_	_
11-11	2712-2714	by	_	_	_	_
11-12	2715-2724	measuring	_	_	_	_
11-13	2725-2728	the	abstract[141]	new[141]	coref	12-9[163_141]
11-14	2729-2738	intensity	abstract[141]	new[141]	_	_
11-15	2739-2743	from	abstract[141]	new[141]	_	_
11-16	2744-2755	fluorescent	abstract[141]	new[141]	_	_
11-17	2756-2764	labelled	_	_	_	_
11-18	2765-2772	dextran	substance	giv	coref	12-32
11-19	2773-2774	(	_	_	_	_
11-20	2775-2779	FITC	abstract	new	_	_
11-21	2780-2783	and	_	_	_	_
11-22	2784-2789	Alexa	abstract[144]	new[144]	_	_
11-23	2790-2793	488	abstract[144]|quantity	new[144]|new	_	_
11-24	2794-2795	;	_	_	_	_
11-25	2796-2800	with	_	_	_	_
11-26	2801-2802	a	abstract[147]	new[147]	_	_
11-27	2803-2810	surface	place|abstract[147]	giv|new[147]	coref	11-61
11-28	2811-2819	coverage	abstract[147]	new[147]	_	_
11-29	2820-2827	ranging	_	_	_	_
11-30	2828-2832	from	_	_	_	_
11-31	2833-2836	1.8	_	_	_	_
11-32	2837-2838	×	_	_	_	_
11-33	2839-2843	1011	_	_	_	_
11-34	2844-2846	to	_	_	_	_
11-35	2847-2850	2.1	object[149]	new[149]	coref	18-40[251_149]
11-36	2851-2852	×	object[149]	new[149]	_	_
11-37	2853-2857	1012	quantity|object[149]	new|new[149]	_	_
11-38	2858-2869	immobilized	object[149]	new[149]	_	_
11-39	2870-2881	fluorescent	object[149]	new[149]	_	_
11-40	2882-2891	molecules	object[149]	new[149]	_	_
11-41	2892-2895	per	object[149]	new[149]	_	_
11-42	2896-2899	cm2	object[149]|quantity	new[149]|new	_	_
11-43	2900-2901	)	object[149]	new[149]	_	_
11-44	2902-2906	over	object[149]	new[149]	_	_
11-45	2907-2908	a	object[149]|abstract[153]	new[149]|giv[153]	coref	16-12[227_153]
11-46	2909-2916	glucose	object[149]|substance|abstract[153]	new[149]|giv|giv[153]	_	_
11-47	2917-2930	concentration	object[149]|abstract|abstract[153]	new[149]|new|giv[153]	_	_
11-48	2931-2936	range	object[149]|abstract[153]	new[149]|giv[153]	_	_
11-49	2937-2941	from	object[149]|abstract[153]	new[149]|giv[153]	_	_
11-50	2942-2943	0	object[149]|abstract[153]|quantity	new[149]|giv[153]|new	_	_
11-51	2944-2946	to	object[149]|abstract[153]	new[149]|giv[153]	_	_
11-52	2947-2949	40	object[149]|abstract[153]|quantity[155]	new[149]|giv[153]|new[155]	_	_
11-53	2950-2952	mM	object[149]|abstract[153]|quantity[155]	new[149]|giv[153]|new[155]	_	_
11-54	2953-2954	,	_	_	_	_
11-55	2955-2962	whereas	_	_	_	_
11-56	2963-2966	any	abstract[156]	new[156]	_	_
11-57	2967-2977	structural	abstract[156]	new[156]	_	_
11-58	2978-2985	changes	abstract[156]	new[156]	_	_
11-59	2986-2988	to	abstract[156]	new[156]	_	_
11-60	2989-2992	the	abstract[156]|abstract[158]	new[156]|new[158]	_	_
11-61	2993-3000	surface	abstract[156]|place|abstract[158]	new[156]|giv|new[158]	coref	12-20
11-62	3001-3011	topography	abstract[156]|abstract[158]	new[156]|new[158]	_	_
11-63	3012-3016	were	_	_	_	_
11-64	3017-3029	investigated	_	_	_	_
11-65	3030-3035	using	_	_	_	_
11-66	3036-3039	AFM	event	new	_	_
11-67	3040-3041	.	_	_	_	_

#Text=These complementing measurements verified that a change in the fluorescence intensity was accompanied with a change in the average surface roughness , and thereby the composition ( addition and loss of dextran ) at the sample surface .
12-1	3042-3047	These	abstract[160]	new[160]	coref	17-16[236_160]
12-2	3048-3061	complementing	abstract[160]	new[160]	_	_
12-3	3062-3074	measurements	abstract[160]	new[160]	_	_
12-4	3075-3083	verified	_	_	_	_
12-5	3084-3088	that	_	_	_	_
12-6	3089-3090	a	abstract[161]	new[161]	_	_
12-7	3091-3097	change	abstract[161]	new[161]	_	_
12-8	3098-3100	in	abstract[161]	new[161]	_	_
12-9	3101-3104	the	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
12-10	3105-3117	fluorescence	abstract[161]|abstract|abstract[163]	new[161]|new|giv[163]	_	_
12-11	3118-3127	intensity	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
12-12	3128-3131	was	_	_	_	_
12-13	3132-3143	accompanied	_	_	_	_
12-14	3144-3148	with	_	_	_	_
12-15	3149-3150	a	abstract[164]	new[164]	coref	15-20[223_164]
12-16	3151-3157	change	abstract[164]	new[164]	_	_
12-17	3158-3160	in	abstract[164]	new[164]	_	_
12-18	3161-3164	the	abstract[164]|abstract[166]	new[164]|new[166]	_	_
12-19	3165-3172	average	abstract[164]|abstract[166]	new[164]|new[166]	_	_
12-20	3173-3180	surface	abstract[164]|place|abstract[166]	new[164]|giv|new[166]	coref	12-35[172_0]
12-21	3181-3190	roughness	abstract[164]|abstract[166]	new[164]|new[166]	_	_
12-22	3191-3192	,	_	_	_	_
12-23	3193-3196	and	_	_	_	_
12-24	3197-3204	thereby	abstract[167]	giv[167]	_	_
12-25	3205-3208	the	abstract[167]	giv[167]	_	_
12-26	3209-3220	composition	abstract[167]	giv[167]	_	_
12-27	3221-3222	(	_	_	_	_
12-28	3223-3231	addition	abstract	new	_	_
12-29	3232-3235	and	_	_	_	_
12-30	3236-3240	loss	abstract[169]	new[169]	_	_
12-31	3241-3243	of	abstract[169]	new[169]	_	_
12-32	3244-3251	dextran	abstract[169]|substance	new[169]|giv	_	_
12-33	3252-3253	)	abstract[169]	new[169]	_	_
12-34	3254-3256	at	abstract[169]	new[169]	_	_
12-35	3257-3260	the	abstract[169]|place[172]	new[169]|giv[172]	_	_
12-36	3261-3267	sample	abstract[169]|object|place[172]	new[169]|new|giv[172]	_	_
12-37	3268-3275	surface	abstract[169]|place[172]	new[169]|giv[172]	_	_
12-38	3276-3277	.	_	_	_	_

#Text=H. Aldewachi and coworkers in their paper on the Study of the Stability of Functionalized Gold Nanoparticles for the Colorimetric Detection of Dipeptidyl Peptidase IV report on three stabilization strategies of gold nanoparticles and their practical applications for the visual detection of dipeptidyl peptidase IV ( DPP-IV ) , an enzyme of high clinical importance , especially as a diagnostic and prognostic marker of various inflammatory disorders and tumors .
13-1	3278-3280	H.	person[173]	new[173]	_	_
13-2	3281-3290	Aldewachi	person[173]	new[173]	_	_
13-3	3291-3294	and	_	_	_	_
13-4	3295-3304	coworkers	person[174]	giv[174]	_	_
13-5	3305-3307	in	person[174]	giv[174]	_	_
13-6	3308-3313	their	person[174]|abstract[175]	giv[174]|giv[175]	_	_
13-7	3314-3319	paper	person[174]|abstract[175]	giv[174]|giv[175]	_	_
13-8	3320-3322	on	person[174]|abstract[175]	giv[174]|giv[175]	_	_
13-9	3323-3326	the	person[174]|abstract[175]|abstract[176]	giv[174]|giv[175]|new[176]	_	_
13-10	3327-3332	Study	person[174]|abstract[175]|abstract[176]	giv[174]|giv[175]|new[176]	_	_
13-11	3333-3335	of	person[174]|abstract[175]|abstract[176]	giv[174]|giv[175]|new[176]	_	_
13-12	3336-3339	the	person[174]|abstract[175]|abstract[176]|abstract[177]	giv[174]|giv[175]|new[176]|new[177]	coref	14-38[212_177]
13-13	3340-3349	Stability	person[174]|abstract[175]|abstract[176]|abstract[177]	giv[174]|giv[175]|new[176]|new[177]	_	_
13-14	3350-3352	of	person[174]|abstract[175]|abstract[176]|abstract[177]	giv[174]|giv[175]|new[176]|new[177]	_	_
13-15	3353-3367	Functionalized	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]	giv[174]|giv[175]|new[176]|new[177]|giv[179]	_	_
13-16	3368-3372	Gold	person[174]|abstract[175]|abstract[176]|abstract[177]|substance|object[179]	giv[174]|giv[175]|new[176]|new[177]|new|giv[179]	coref	13-32
13-17	3373-3386	Nanoparticles	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]	giv[174]|giv[175]|new[176]|new[177]|giv[179]	_	_
13-18	3387-3390	for	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]	giv[174]|giv[175]|new[176]|new[177]|giv[179]	_	_
13-19	3391-3394	the	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-20	3395-3407	Colorimetric	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|new|giv[181]	_	_
13-21	3408-3417	Detection	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-22	3418-3420	of	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-23	3421-3431	Dipeptidyl	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract|abstract[183]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new|new[183]	coref	13-43
13-24	3432-3441	Peptidase	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[183]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[183]	_	_
13-25	3442-3444	IV	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|person	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new	_	_
13-26	3445-3451	report	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-27	3452-3454	on	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-28	3455-3460	three	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[186]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[186]	_	_
13-29	3461-3474	stabilization	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract|abstract[186]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new|new[186]	_	_
13-30	3475-3485	strategies	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[186]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[186]	_	_
13-31	3486-3488	of	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[186]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[186]	_	_
13-32	3489-3493	gold	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[186]|substance	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[186]|giv	_	_
13-33	3494-3507	nanoparticles	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[186]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|new[186]	_	_
13-34	3508-3511	and	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]	_	_
13-35	3512-3517	their	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]	_	_
13-36	3518-3527	practical	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]	_	_
13-37	3528-3540	applications	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]	_	_
13-38	3541-3544	for	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]	_	_
13-39	3545-3548	the	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]	_	_
13-40	3549-3555	visual	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]	_	_
13-41	3556-3565	detection	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]	_	_
13-42	3566-3568	of	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]	_	_
13-43	3569-3579	dipeptidyl	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]|substance|object[192]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]|giv|new[192]	appos	13-47[0_192]
13-44	3580-3589	peptidase	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]|substance|object[192]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]|new|new[192]	_	_
13-45	3590-3592	IV	person[174]|abstract[175]|abstract[176]|abstract[177]|object[179]|abstract[181]|abstract[188]|abstract[189]|object[192]	giv[174]|giv[175]|new[176]|new[177]|giv[179]|giv[181]|giv[188]|new[189]|new[192]	_	_
13-46	3593-3594	(	_	_	_	_
13-47	3595-3601	DPP-IV	object	giv	coref	17-25
13-48	3602-3603	)	_	_	_	_
13-49	3604-3605	,	_	_	_	_
13-50	3606-3608	an	substance[194]	new[194]	_	_
13-51	3609-3615	enzyme	substance[194]	new[194]	_	_
13-52	3616-3618	of	substance[194]	new[194]	_	_
13-53	3619-3623	high	substance[194]|abstract[195]	new[194]|new[195]	_	_
13-54	3624-3632	clinical	substance[194]|abstract[195]	new[194]|new[195]	_	_
13-55	3633-3643	importance	substance[194]|abstract[195]	new[194]|new[195]	_	_
13-56	3644-3645	,	_	_	_	_
13-57	3646-3656	especially	abstract[196]	new[196]	_	_
13-58	3657-3659	as	abstract[196]	new[196]	_	_
13-59	3660-3661	a	abstract[196]	new[196]	_	_
13-60	3662-3672	diagnostic	abstract[196]	new[196]	_	_
13-61	3673-3676	and	abstract[196]	new[196]	_	_
13-62	3677-3687	prognostic	abstract[196]	new[196]	_	_
13-63	3688-3694	marker	abstract[196]	new[196]	_	_
13-64	3695-3697	of	abstract[196]	new[196]	_	_
13-65	3698-3705	various	abstract[196]|abstract[197]	new[196]|new[197]	_	_
13-66	3706-3718	inflammatory	abstract[196]|abstract[197]	new[196]|new[197]	_	_
13-67	3719-3728	disorders	abstract[196]|abstract[197]	new[196]|new[197]	_	_
13-68	3729-3732	and	abstract[196]	new[196]	_	_
13-69	3733-3739	tumors	abstract[196]|abstract	new[196]|new	_	_
13-70	3740-3741	.	_	_	_	_

#Text=The first strategy used the incorporation of a PEGylated sequence with a dithiol anchor to create biorecognition ligands ; the other two strategies used a peptide sequence ( CALNN ) selected from 58 peptide sequences tested for their high stability and resistance to electrolyte-induced Au NP aggregation .
14-1	3742-3745	The	abstract[199]	new[199]	_	_
14-2	3746-3751	first	abstract[199]	new[199]	_	_
14-3	3752-3760	strategy	abstract[199]	new[199]	_	_
14-4	3761-3765	used	_	_	_	_
14-5	3766-3769	the	abstract[200]	new[200]	_	_
14-6	3770-3783	incorporation	abstract[200]	new[200]	_	_
14-7	3784-3786	of	abstract[200]	new[200]	_	_
14-8	3787-3788	a	abstract[200]|abstract[201]	new[200]|new[201]	coref	14-25[207_201]
14-9	3789-3798	PEGylated	abstract[200]|abstract[201]	new[200]|new[201]	_	_
14-10	3799-3807	sequence	abstract[200]|abstract[201]	new[200]|new[201]	_	_
14-11	3808-3812	with	abstract[200]|abstract[201]	new[200]|new[201]	_	_
14-12	3813-3814	a	abstract[200]|abstract[201]|object[203]	new[200]|new[201]|new[203]	_	_
14-13	3815-3822	dithiol	abstract[200]|abstract[201]|abstract|object[203]	new[200]|new[201]|new|new[203]	_	_
14-14	3823-3829	anchor	abstract[200]|abstract[201]|object[203]	new[200]|new[201]|new[203]	_	_
14-15	3830-3832	to	_	_	_	_
14-16	3833-3839	create	_	_	_	_
14-17	3840-3854	biorecognition	abstract[204]	new[204]	_	_
14-18	3855-3862	ligands	abstract[204]	new[204]	_	_
14-19	3863-3864	;	_	_	_	_
14-20	3865-3868	the	abstract[205]	new[205]	_	_
14-21	3869-3874	other	abstract[205]	new[205]	_	_
14-22	3875-3878	two	abstract[205]	new[205]	_	_
14-23	3879-3889	strategies	abstract[205]	new[205]	_	_
14-24	3890-3894	used	_	_	_	_
14-25	3895-3896	a	abstract[207]	giv[207]	_	_
14-26	3897-3904	peptide	abstract|abstract[207]	giv|giv[207]	coref	14-34
14-27	3905-3913	sequence	abstract[207]	giv[207]	_	_
14-28	3914-3915	(	_	_	_	_
14-29	3916-3921	CALNN	object	new	_	_
14-30	3922-3923	)	_	_	_	_
14-31	3924-3932	selected	_	_	_	_
14-32	3933-3937	from	_	_	_	_
14-33	3938-3940	58	abstract[210]	new[210]	ana	14-38[0_210]
14-34	3941-3948	peptide	abstract|abstract[210]	giv|new[210]	_	_
14-35	3949-3958	sequences	abstract[210]	new[210]	_	_
14-36	3959-3965	tested	_	_	_	_
14-37	3966-3969	for	_	_	_	_
14-38	3970-3975	their	abstract|abstract[212]	giv|giv[212]	coref	16-22[230_212]
14-39	3976-3980	high	abstract[212]	giv[212]	_	_
14-40	3981-3990	stability	abstract[212]	giv[212]	_	_
14-41	3991-3994	and	_	_	_	_
14-42	3995-4005	resistance	abstract[213]	new[213]	_	_
14-43	4006-4008	to	abstract[213]	new[213]	_	_
14-44	4009-4028	electrolyte-induced	abstract[213]|abstract[216]	new[213]|new[216]	_	_
14-45	4029-4031	Au	abstract[213]|person|abstract[216]	new[213]|new|new[216]	_	_
14-46	4032-4034	NP	abstract[213]|organization|abstract[216]	new[213]|new|new[216]	_	_
14-47	4035-4046	aggregation	abstract[213]|abstract[216]	new[213]|new[216]	_	_
14-48	4047-4048	.	_	_	_	_

#Text=DPP-IV/CD26 activity using the three approaches was detected under optimal conditions and only C/G-capped AuNPs showed a response with a color change when incubated with DPP-IV/CD26 .
15-1	4049-4060	DPP-IV/CD26	abstract[217]	giv[217]	coref	17-25[239_217]
15-2	4061-4069	activity	abstract[217]	giv[217]	_	_
15-3	4070-4075	using	_	_	_	_
15-4	4076-4079	the	abstract[218]	new[218]	_	_
15-5	4080-4085	three	abstract[218]	new[218]	_	_
15-6	4086-4096	approaches	abstract[218]	new[218]	_	_
15-7	4097-4100	was	_	_	_	_
15-8	4101-4109	detected	_	_	_	_
15-9	4110-4115	under	_	_	_	_
15-10	4116-4123	optimal	abstract[219]	new[219]	coref	19-7[263_219]
15-11	4124-4134	conditions	abstract[219]	new[219]	_	_
15-12	4135-4138	and	_	_	_	_
15-13	4139-4143	only	abstract[220]	new[220]	coref	16-1[225_220]
15-14	4144-4154	C/G-capped	abstract[220]	new[220]	_	_
15-15	4155-4160	AuNPs	abstract[220]	new[220]	_	_
15-16	4161-4167	showed	_	_	_	_
15-17	4168-4169	a	abstract[221]	new[221]	_	_
15-18	4170-4178	response	abstract[221]	new[221]	_	_
15-19	4179-4183	with	abstract[221]	new[221]	_	_
15-20	4184-4185	a	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
15-21	4186-4191	color	abstract[221]|abstract|abstract[223]	new[221]|new|giv[223]	_	_
15-22	4192-4198	change	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
15-23	4199-4203	when	_	_	_	_
15-24	4204-4213	incubated	_	_	_	_
15-25	4214-4218	with	_	_	_	_
15-26	4219-4230	DPP-IV/CD26	abstract	new	_	_
15-27	4231-4232	.	_	_	_	_

#Text=C/G-capped AuNPs were less sensitive than the monofunctionalized systems , with a dynamic range of 10 – 30 U/L but with very high stability in ionic solutions .
16-1	4233-4243	C/G-capped	abstract[225]	giv[225]	_	_
16-2	4244-4249	AuNPs	abstract[225]	giv[225]	_	_
16-3	4250-4254	were	_	_	_	_
16-4	4255-4259	less	_	_	_	_
16-5	4260-4269	sensitive	_	_	_	_
16-6	4270-4274	than	_	_	_	_
16-7	4275-4278	the	object[226]	giv[226]	_	_
16-8	4279-4297	monofunctionalized	object[226]	giv[226]	_	_
16-9	4298-4305	systems	object[226]	giv[226]	_	_
16-10	4306-4307	,	_	_	_	_
16-11	4308-4312	with	_	_	_	_
16-12	4313-4314	a	abstract[227]	giv[227]	_	_
16-13	4315-4322	dynamic	abstract[227]	giv[227]	_	_
16-14	4323-4328	range	abstract[227]	giv[227]	_	_
16-15	4329-4331	of	abstract[227]	giv[227]	_	_
16-16	4332-4334	10	abstract[227]|quantity	giv[227]|new	_	_
16-17	4335-4336	–	abstract[227]	giv[227]	_	_
16-18	4337-4339	30	abstract[227]|quantity[229]	giv[227]|new[229]	_	_
16-19	4340-4343	U/L	abstract[227]|quantity[229]	giv[227]|new[229]	_	_
16-20	4344-4347	but	_	_	_	_
16-21	4348-4352	with	_	_	_	_
16-22	4353-4357	very	abstract[230]	giv[230]	_	_
16-23	4358-4362	high	abstract[230]	giv[230]	_	_
16-24	4363-4372	stability	abstract[230]	giv[230]	_	_
16-25	4373-4375	in	abstract[230]	giv[230]	_	_
16-26	4376-4381	ionic	abstract[230]|substance[231]	giv[230]|new[231]	_	_
16-27	4382-4391	solutions	abstract[230]|substance[231]	giv[230]|new[231]	_	_
16-28	4392-4393	.	_	_	_	_

#Text=The developed biofunctionalized assay was successfully evaluated by gel electrophoresis , zeta potential , and hydrodynamic radius measurements and tested for the assay of DPP-IV activity .
17-1	4394-4397	The	object[232]	new[232]	coref	17-22[237_232]
17-2	4398-4407	developed	object[232]	new[232]	_	_
17-3	4408-4425	biofunctionalized	object[232]	new[232]	_	_
17-4	4426-4431	assay	object[232]	new[232]	_	_
17-5	4432-4435	was	_	_	_	_
17-6	4436-4448	successfully	_	_	_	_
17-7	4449-4458	evaluated	_	_	_	_
17-8	4459-4461	by	_	_	_	_
17-9	4462-4465	gel	substance|object[234]	new|new[234]	_	_
17-10	4466-4481	electrophoresis	object[234]	new[234]	_	_
17-11	4482-4483	,	_	_	_	_
17-12	4484-4488	zeta	_	_	_	_
17-13	4489-4498	potential	_	_	_	_
17-14	4499-4500	,	_	_	_	_
17-15	4501-4504	and	_	_	_	_
17-16	4505-4517	hydrodynamic	abstract[236]	giv[236]	_	_
17-17	4518-4524	radius	abstract|abstract[236]	new|giv[236]	_	_
17-18	4525-4537	measurements	abstract[236]	giv[236]	_	_
17-19	4538-4541	and	_	_	_	_
17-20	4542-4548	tested	_	_	_	_
17-21	4549-4552	for	_	_	_	_
17-22	4553-4556	the	object[237]	giv[237]	_	_
17-23	4557-4562	assay	object[237]	giv[237]	_	_
17-24	4563-4565	of	object[237]	giv[237]	_	_
17-25	4566-4572	DPP-IV	object[237]|place|abstract[239]	giv[237]|giv|giv[239]	_	_
17-26	4573-4581	activity	object[237]|abstract[239]	giv[237]|giv[239]	_	_
17-27	4582-4583	.	_	_	_	_

#Text=Finally , in the review : Biosensor Applications of Electrodeposited Nanostructures , the author K.J. Stine traces an overview on the area of developing biosensors based on electrodeposited nanostructures , which has many possible applications to the detection of small molecules , metabolites , protein antigens , oligonucleotides , and other targets , including bacteria and viruses .
18-1	4584-4591	Finally	_	_	_	_
18-2	4592-4593	,	_	_	_	_
18-3	4594-4596	in	_	_	_	_
18-4	4597-4600	the	abstract[240]	new[240]	appos	18-7[242_240]
18-5	4601-4607	review	abstract[240]	new[240]	_	_
18-6	4608-4609	:	_	_	_	_
18-7	4610-4619	Biosensor	person|abstract[242]	giv|giv[242]	coref	18-33[249_242]
18-8	4620-4632	Applications	abstract[242]	giv[242]	_	_
18-9	4633-4635	of	abstract[242]	giv[242]	_	_
18-10	4636-4652	Electrodeposited	abstract[242]|object[243]	giv[242]|new[243]	coref	18-28[248_243]
18-11	4653-4667	Nanostructures	abstract[242]|object[243]	giv[242]|new[243]	_	_
18-12	4668-4669	,	_	_	_	_
18-13	4670-4673	the	person[244]	new[244]	_	_
18-14	4674-4680	author	person[244]	new[244]	_	_
18-15	4681-4685	K.J.	person[244]	new[244]	_	_
18-16	4686-4691	Stine	person[244]	new[244]	_	_
18-17	4692-4698	traces	_	_	_	_
18-18	4699-4701	an	abstract[245]	new[245]	_	_
18-19	4702-4710	overview	abstract[245]	new[245]	_	_
18-20	4711-4713	on	abstract[245]	new[245]	_	_
18-21	4714-4717	the	abstract[245]|abstract[246]	new[245]|new[246]	_	_
18-22	4718-4722	area	abstract[245]|abstract[246]	new[245]|new[246]	_	_
18-23	4723-4725	of	_	_	_	_
18-24	4726-4736	developing	_	_	_	_
18-25	4737-4747	biosensors	substance	giv	_	_
18-26	4748-4753	based	_	_	_	_
18-27	4754-4756	on	_	_	_	_
18-28	4757-4773	electrodeposited	object[248]	giv[248]	_	_
18-29	4774-4788	nanostructures	object[248]	giv[248]	_	_
18-30	4789-4790	,	_	_	_	_
18-31	4791-4796	which	_	_	_	_
18-32	4797-4800	has	_	_	_	_
18-33	4801-4805	many	abstract[249]	giv[249]	_	_
18-34	4806-4814	possible	abstract[249]	giv[249]	_	_
18-35	4815-4827	applications	abstract[249]	giv[249]	_	_
18-36	4828-4830	to	abstract[249]	giv[249]	_	_
18-37	4831-4834	the	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-38	4835-4844	detection	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-39	4845-4847	of	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-40	4848-4853	small	abstract[249]|abstract[250]|object[251]	giv[249]|new[250]|giv[251]	_	_
18-41	4854-4863	molecules	abstract[249]|abstract[250]|object[251]	giv[249]|new[250]|giv[251]	_	_
18-42	4864-4865	,	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-43	4866-4877	metabolites	abstract[249]|abstract[250]|substance	giv[249]|new[250]|new	_	_
18-44	4878-4879	,	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-45	4880-4887	protein	abstract[249]|abstract[250]|substance|substance[254]	giv[249]|new[250]|giv|new[254]	_	_
18-46	4888-4896	antigens	abstract[249]|abstract[250]|substance[254]	giv[249]|new[250]|new[254]	_	_
18-47	4897-4898	,	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-48	4899-4915	oligonucleotides	abstract[249]|abstract[250]|substance	giv[249]|new[250]|new	coref	20-21[273_0]
18-49	4916-4917	,	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-50	4918-4921	and	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
18-51	4922-4927	other	abstract[249]|abstract[250]|abstract[256]	giv[249]|new[250]|new[256]	coref	20-1[266_256]
18-52	4928-4935	targets	abstract[249]|abstract[250]|abstract[256]	giv[249]|new[250]|new[256]	_	_
18-53	4936-4937	,	abstract[249]|abstract[250]|abstract[256]	giv[249]|new[250]|new[256]	_	_
18-54	4938-4947	including	abstract[249]|abstract[250]|abstract[256]	giv[249]|new[250]|new[256]	_	_
18-55	4948-4956	bacteria	abstract[249]|abstract[250]|abstract[256]|animal	giv[249]|new[250]|new[256]|new	_	_
18-56	4957-4960	and	abstract[249]|abstract[250]|abstract[256]	giv[249]|new[250]|new[256]	_	_
18-57	4961-4968	viruses	abstract[249]|abstract[250]|abstract[256]|animal	giv[249]|new[250]|new[256]|new	_	_
18-58	4969-4970	.	_	_	_	_

#Text=The variety of substrate electrodes and preparation conditions can produce a vast range of structures .
19-1	4971-4974	The	abstract[259]	new[259]	_	_
19-2	4975-4982	variety	abstract[259]	new[259]	_	_
19-3	4983-4985	of	abstract[259]	new[259]	_	_
19-4	4986-4995	substrate	abstract[259]|object|object[261]	new[259]|giv|giv[261]	_	_
19-5	4996-5006	electrodes	abstract[259]|object[261]	new[259]|giv[261]	_	_
19-6	5007-5010	and	abstract[259]|object[261]	new[259]|giv[261]	_	_
19-7	5011-5022	preparation	abstract[259]|object[261]|abstract|abstract[263]	new[259]|giv[261]|new|giv[263]	_	_
19-8	5023-5033	conditions	abstract[259]|object[261]|abstract[263]	new[259]|giv[261]|giv[263]	_	_
19-9	5034-5037	can	_	_	_	_
19-10	5038-5045	produce	_	_	_	_
19-11	5046-5047	a	abstract[264]	new[264]	_	_
19-12	5048-5052	vast	abstract[264]	new[264]	_	_
19-13	5053-5058	range	abstract[264]	new[264]	_	_
19-14	5059-5061	of	abstract[264]	new[264]	_	_
19-15	5062-5072	structures	abstract[264]|abstract	new[264]|new	_	_
19-16	5073-5074	.	_	_	_	_

#Text=Many additional targets of high interest for the development of diagnostics , such as glycoproteins , circulating tumor cells , circulating oligonucleotides , microRNAs , and content in microvesicles remain unexplored .
20-1	5075-5079	Many	abstract[266]	giv[266]	_	_
20-2	5080-5090	additional	abstract[266]	giv[266]	_	_
20-3	5091-5098	targets	abstract[266]	giv[266]	_	_
20-4	5099-5101	of	abstract[266]	giv[266]	_	_
20-5	5102-5106	high	abstract[266]|abstract[267]	giv[266]|new[267]	_	_
20-6	5107-5115	interest	abstract[266]|abstract[267]	giv[266]|new[267]	_	_
20-7	5116-5119	for	abstract[266]|abstract[267]	giv[266]|new[267]	_	_
20-8	5120-5123	the	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-9	5124-5135	development	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-10	5136-5138	of	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-11	5139-5150	diagnostics	abstract[266]|abstract[267]|abstract[268]|abstract	giv[266]|new[267]|new[268]|new	_	_
20-12	5151-5152	,	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-13	5153-5157	such	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-14	5158-5160	as	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-15	5161-5174	glycoproteins	abstract[266]|abstract[267]|abstract[268]|substance	giv[266]|new[267]|new[268]|new	_	_
20-16	5175-5176	,	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-17	5177-5188	circulating	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-18	5189-5194	tumor	abstract[266]|abstract[267]|abstract[268]|abstract|object[272]	giv[266]|new[267]|new[268]|new|giv[272]	_	_
20-19	5195-5200	cells	abstract[266]|abstract[267]|abstract[268]|object[272]	giv[266]|new[267]|new[268]|giv[272]	_	_
20-20	5201-5202	,	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-21	5203-5214	circulating	abstract[266]|abstract[267]|abstract[268]|substance[273]	giv[266]|new[267]|new[268]|giv[273]	_	_
20-22	5215-5231	oligonucleotides	abstract[266]|abstract[267]|abstract[268]|substance[273]	giv[266]|new[267]|new[268]|giv[273]	_	_
20-23	5232-5233	,	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-24	5234-5243	microRNAs	abstract[266]|abstract[267]|abstract[268]|object	giv[266]|new[267]|new[268]|new	_	_
20-25	5244-5245	,	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-26	5246-5249	and	abstract[266]|abstract[267]|abstract[268]	giv[266]|new[267]|new[268]	_	_
20-27	5250-5257	content	abstract[266]|abstract[267]|abstract[268]|abstract[275]	giv[266]|new[267]|new[268]|new[275]	_	_
20-28	5258-5260	in	abstract[266]|abstract[267]|abstract[268]|abstract[275]	giv[266]|new[267]|new[268]|new[275]	_	_
20-29	5261-5274	microvesicles	abstract[266]|abstract[267]|abstract[268]|abstract[275]|object	giv[266]|new[267]|new[268]|new[275]|new	_	_
20-30	5275-5281	remain	_	_	_	_
20-31	5282-5292	unexplored	_	_	_	_
20-32	5293-5294	.	_	_	_	_
